[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 28 of about 28
1. Suzuki K, Kobayashi M, Tokue A: [A case of advanced rhabdomyosarcoma of the spermatic cord who occurred epilepsy-like symptoms, but was completely responded to chemotherapy]. Nihon Hinyokika Gakkai Zasshi; 2004 Jul;95(5):733-7
Hazardous Substances Data Bank. DIAZEPAM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced rhabdomyosarcoma of the spermatic cord who occurred epilepsy-like symptoms, but was completely responded to chemotherapy].
  • On the diagnosis of left intrascrotal tumor, left high orchiectomy with partial scrotal skin resection was performed.
  • Pathological examination of the specimen and systemic metastasis survey revealed embryonal rhabdomyosarcoma of left spermatic cord with multiple lung metastasis (Intergroup Rhabdomyosarcoma Study Group IV).
  • Systemic chemotherapy with etoposide (VP-16), cisplatin (CDDP), and ifosfamide (IFO) (VIP therapy) was started.
  • Although epilepsy-like symptoms occurred at the first course of VIP therapy, these symptoms immediately improved by diazepam administration.
  • On the other hand, his multiple lung metastasis disappeared after the second course of VIP therapy.
  • Although IFO may be effective in rhabdomyosarcoma, the toxicity of various nervous systems may be discovered.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Epilepsy / drug therapy. Genital Neoplasms, Male / drug therapy. Rhabdomyosarcoma / drug therapy. Spermatic Cord
  • [MeSH-minor] Adult. Anticonvulsants / therapeutic use. Cisplatin / administration & dosage. Cisplatin / adverse effects. Diazepam / therapeutic use. Etoposide / administration & dosage. Etoposide / adverse effects. Humans. Ifosfamide / administration & dosage. Ifosfamide / adverse effects. Male

  • Genetic Alliance. consumer health - Epilepsy.
  • MedlinePlus Health Information. consumer health - Epilepsy.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15354722.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Anticonvulsants; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; Q3JTX2Q7TU / Diazepam; UM20QQM95Y / Ifosfamide; ICE protocol 1
  •  go-up   go-down


2. Brunasso AM, Delfino C, Ketabchi S, Difonzo EM, Massone C: Papules arising after radiotherapy for rhabdomyosarcoma. Acta Dermatovenerol Alp Pannonica Adriat; 2009 Mar;18(1):24-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papules arising after radiotherapy for rhabdomyosarcoma.
  • Radiation therapy, even at low doses, can induce a wide spectrum of vascular skin proliferations ranging from nonmalignant ones, such as benign lymphangiomatous papules (BLAP), to frankly malignant pathologies, such as angiosarcoma.
  • We describe a 50-year-old Caucasian woman with a past history of uterine rhabdomyosarcoma, treated 22 years prior with surgical excision, chemotherapy, and radiotherapy.
  • She presented with a few skin-colored papules and a clear discharge located in the previously irradiated area (right inguinal region).
  • A diagnosis of BLAP following radiotherapy for uterine rhabdomyosarcoma was made.
  • [MeSH-major] Lymphangioma / etiology. Neoplasms, Radiation-Induced / etiology. Rhabdomyosarcoma / radiotherapy. Skin Neoplasms / etiology. Uterine Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19350189.001).
  • [ISSN] 1318-4458
  • [Journal-full-title] Acta dermatovenerologica Alpina, Pannonica, et Adriatica
  • [ISO-abbreviation] Acta Dermatovenerol Alp Pannonica Adriat
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Slovenia
  •  go-up   go-down


3. Ozeki Z, Kobayashi S, Machida T, Kobayashi T, Oka K, Ishizaka K, Oka T: [Alveolar rhabdomyosarcoma originating in spermatic cord: a case report]. Hinyokika Kiyo; 2004 Sep;50(9):653-5
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Alveolar rhabdomyosarcoma originating in spermatic cord: a case report].
  • A thumb head-sized tumor was palpated through the skin on the left spermatic cord.
  • Pathological examination revealed alveolar rhabdomyosarcoma with positive surgical margin.
  • Radical inguinal orchiectomy with combined chemotherapy using vincristine, dactinomycin, and ifosfamide (VAI) was performed.
  • [MeSH-major] Genital Neoplasms, Male / surgery. Orchiectomy. Rhabdomyosarcoma, Alveolar / surgery. Spermatic Cord
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Dactinomycin / administration & dosage. Drug Administration Schedule. Humans. Ifosfamide / administration & dosage. Male. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Rhabdomyosarcoma alveolar.
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15518135.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


Advertisement
4. Lin HF, Lui CC, Hsu HC, Lin SA: Orbital exenteration for secondary orbital tumors: a series of seven cases. Chang Gung Med J; 2002 Sep;25(9):599-605

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It entails the removal of the eyeball together with its extraocular muscles and other soft tissues.
  • Primary lesions, histopathological examination results, treatments, and recurrences are discussed.
  • RESULTS: Classification of the 7 patients showed that 2 had basal cell carcinoma of the skin, 2 had squamous cell carcinoma of the conjunctiva, 1 had squamous cell carcinoma of the paranasal sinus, 1 had rhabdomyosarcoma of the paranasal sinus, and 1 had intracranial meningioma.
  • Radiotherapy was performed in 6 of the patients and chemotherapy in 2.
  • CONCLUSION: Secondary orbital tumors involved the orbit from adjacent tissues: paranasal sinuses, nasopharynx, lacrimal sac, conjunctiva, eyelid, intraocular tissue, and intracranial tissues.
  • [MeSH-minor] Adult. Aged. Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / surgery. Female. Humans. Male. Middle Aged. Rhabdomyosarcoma / surgery. Surgical Flaps

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12479621.001).
  • [ISSN] 2072-0939
  • [Journal-full-title] Chang Gung medical journal
  • [ISO-abbreviation] Chang Gung Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


5. Tsuchisaka A, Usui Y, Goto H, Nagai T, Matsubayashi J, Izumi M, Suzuki S: [Two cases of orbital embryonal rhabdomyosarcoma with chromosome aberration]. Nippon Ganka Gakkai Zasshi; 2010 Apr;114(4):374-80
Genetic Alliance. consumer health - Rhabdomyosarcoma embryonal.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of orbital embryonal rhabdomyosarcoma with chromosome aberration].
  • PURPOSE: Two cases of pediatric orbital rhabdomyosarcoma leading to visual dysfunction with rapid growth.
  • Based on histopathology and clinical examination, diagnosis of embryonal rhabdomyosarcoma was made.
  • MRI revealed a tumor under the skin of the upper palpebra extending to the orbit.
  • Based on histopathology and clinical examination, diagnosis of embryonal rhabdomyosarcoma was made.
  • Both patients subsequently underwent chemotherapy and local radiotherapy and no recurrence has been detected over 1 year.
  • CONCLUSION: Although rhabdomyosarcoma of the orbit often progresses rapidly and may cause visual disturbances, favorable outcome can be expected by proper management especially in cases with certain histopathological types.
  • A comprehensive approach will be required to elucidate the pathogenesis of orbital rhabdomyosarcoma and genetic abnormalities.
  • [MeSH-major] Chromosome Aberrations. Orbital Neoplasms / genetics. Polyploidy. Rhabdomyosarcoma, Embryonal / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20432963.001).
  • [ISSN] 0029-0203
  • [Journal-full-title] Nippon Ganka Gakkai zasshi
  • [ISO-abbreviation] Nippon Ganka Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


6. Rodriguez-Galindo C, Hill DA, Onyekwere O, Pin N, Rao BN, Hoffer FA, Kun LE, Pappo AS, Santana VM: Neonatal alveolar rhabdomyosarcoma with skin and brain metastases. Cancer; 2001 Sep 15;92(6):1613-20
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neonatal alveolar rhabdomyosarcoma with skin and brain metastases.
  • RESULTS: One patient with embryonal RMS was treated successfully with a combination of systemic chemotherapy and local control measures.
  • Two of them had multiple skin and subcutaneous metastatic nodules at the time of diagnosis and developed brain metastases early in their course.
  • Three other similar cases of neonatal alveolar RMS with metastases to the skin and brain have been reported in the literature.
  • This syndrome is characterized by alveolar histology, multiple skin and subcutaneous metastases, and fatal outcome as the result of early brain metastasis.
  • [MeSH-major] Brain Neoplasms / secondary. Rhabdomyosarcoma, Alveolar / pathology. Skin Neoplasms / secondary. Soft Tissue Neoplasms / pathology

  • Genetic Alliance. consumer health - Rhabdomyosarcoma alveolar.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 American Cancer Society.
  • (PMID = 11745240.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / PHS HHS / / LA-23099; United States / NCI NIH HHS / CA / P30 CA 21765
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


7. Aida K, Monia K, Ahlem S, Dominique HT, Becima F, Sylvie F, Ridha KM: Agminated Spitz nevi arising on a nevus spilus after chemotherapy. Pediatr Dermatol; 2010 Jul-Aug;27(4):411-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Agminated Spitz nevi arising on a nevus spilus after chemotherapy.
  • We report here a further case in a child that is original because it is induced by chemotherapy.
  • A 3-year-old boy presented 3 months after the onset of a chemotherapy for a vesico-prostatic rhabdomyosarcoma, multiple pigmented papulo-nodules located on the face, neck, chest wall, and the higher back.
  • Histological examination of three excised nodules led to the diagnosis of Spitz nevus.
  • Some of these criteria are related to NS but we should also take into account the chemotherapy induction and the high number of Spitz nevi.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Nevus, Epithelioid and Spindle Cell / chemically induced. Prostatic Neoplasms / drug therapy. Rhabdomyosarcoma / drug therapy. Skin Neoplasms / chemically induced. Urinary Bladder Neoplasms / drug therapy


8. Theys J, Landuyt W, Nuyts S, Van Mellaert L, van Oosterom A, Lambin P, Anné J: Specific targeting of cytosine deaminase to solid tumors by engineered Clostridium acetobutylicum. Cancer Gene Ther; 2001 Apr;8(4):294-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The presence of severe hypoxia and necrosis in solid tumors offers the potential to apply an anaerobic bacterial enzyme/prodrug approach in cancer treatment.
  • After administration of the recombinant Clostridium to rhabdomyosarcoma bearing rats used as a model, cytosine deaminase could be detected at the tumor site.
  • The results provide evidence for the potential application of Clostrisdium-based therapeutic protein transfer to tumors in anticancer therapy.
  • [MeSH-major] Clostridium / genetics. Nucleoside Deaminases / genetics. Rhabdomyosarcoma / therapy. Skin Neoplasms / therapy
  • [MeSH-minor] Animals. Antifungal Agents / pharmacology. Antimetabolites, Antineoplastic / pharmacology. Antineoplastic Agents, Phytogenic / pharmacology. Cytosine Deaminase. DNA Primers / chemistry. Drug Delivery Systems. Escherichia coli / enzymology. Flucytosine / pharmacology. Fluorouracil / pharmacology. Genetic Therapy. Genetic Vectors / genetics. In Vitro Techniques. Neoplasm Transplantation. Plasmids. Rats. Recombinant Proteins / administration & dosage. Recombinant Proteins / metabolism. Recombinant Proteins / therapeutic use. Stilbenes / pharmacology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUCYTOSINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11393282.001).
  • [ISSN] 0929-1903
  • [Journal-full-title] Cancer gene therapy
  • [ISO-abbreviation] Cancer Gene Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 0 / DNA Primers; 0 / Recombinant Proteins; 0 / Stilbenes; D83282DT06 / Flucytosine; EC 3.5.4.- / Nucleoside Deaminases; EC 3.5.4.1 / Cytosine Deaminase; I5590ES2QZ / fosbretabulin; U3P01618RT / Fluorouracil
  •  go-up   go-down


9. Brecher AR, Reyes-Mugica M, Kamino H, Chang MW: Congenital primary cutaneous rhabdomyosarcoma in a neonate. Pediatr Dermatol; 2003 Jul-Aug;20(4):335-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Congenital primary cutaneous rhabdomyosarcoma in a neonate.
  • We report a case of congenital primary cutaneous rhabdomyosarcoma, solid alveolar type, presenting as a solitary skin lesion on the right upper lip of a 2-week-old infant boy.
  • Rhabdomyosarcoma originates from the embryonic mesenchyme precursor of striated muscle.
  • Congenital alveolar rhabdomyosarcoma is a highly malignant tumor with no record of long-term survivors.
  • Treatment options include chemotherapy, excision, and radiotherapy.
  • This infant's tumor was responsive to chemotherapy and surgery and he was free of disease at the 6-month follow-up.
  • [MeSH-major] Rhabdomyosarcoma, Alveolar / congenital. Rhabdomyosarcoma, Alveolar / pathology. Skin Neoplasms / congenital. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12869157.001).
  • [ISSN] 0736-8046
  • [Journal-full-title] Pediatric dermatology
  • [ISO-abbreviation] Pediatr Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Nakagawa N, Tsuda T, Yamamoto M, Ito T, Futani H, Yamanishi K: Adult cutaneous alveolar rhabdomyosarcoma on the face diagnosed by the expression of PAX3-FKHR gene fusion transcripts. J Dermatol; 2008 Jul;35(7):462-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult cutaneous alveolar rhabdomyosarcoma on the face diagnosed by the expression of PAX3-FKHR gene fusion transcripts.
  • The histology was compatible with alveolar rhabdomyosarcoma, but immunohistochemistry showed that the tumor cells were negative for desmin, alpha-smooth muscle actin and alpha-Sr-1, but were positive for CD56, vimentin and myogenin.
  • The diagnosis of alveolar rhabdomyosarcoma was confirmed by the detection of PAX3-FKHR fusion gene transcripts in the paraffin-embedded tumor tissue.
  • The tumor was unresponsive to chemotherapy with pirarubicin, carboplatin and ifosfamide, and the patient died 9 months after the diagnosis.
  • This adult case of an alveolar rhabdomyosarcoma primarily occurring on the face is very rare, and the detection of PAX3-FKHR fusion gene transcripts was useful for diagnosis of the disease.
  • [MeSH-major] Facial Neoplasms / diagnosis. Oncogene Proteins, Fusion / metabolism. Rhabdomyosarcoma, Alveolar / diagnosis. Skin Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Rhabdomyosarcoma alveolar.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18705836.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion; 0 / PAX3-FKHR fusion protein, human; 0 / RNA, Messenger
  •  go-up   go-down


11. Ilyas EN, Goldsmith K, Lintner R, Manders SM: Rhabdomyosarcoma arising in a giant congenital melanocytic nevus. Cutis; 2004 Jan;73(1):39-43
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rhabdomyosarcoma arising in a giant congenital melanocytic nevus.
  • We report the case of a 6-week-old girl who presented with a pedunculated embryonal rhabdomyosarcoma arising in a giant congenital melanocytic nevus (GCMN) on her lower back.
  • The patient underwent surgical resection of the rhabdomyosarcoma at age 2 months, with subsequent chemotherapy consisting of actinomycin D and vincristine.
  • [MeSH-major] Nevus, Pigmented / pathology. Precancerous Conditions / pathology. Rhabdomyosarcoma / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Biopsy, Needle. Female. Follow-Up Studies. Humans. Immunohistochemistry. Infant. Risk Assessment. Treatment Outcome

  • Genetic Alliance. consumer health - Nevus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14964630.001).
  • [ISSN] 0011-4162
  • [Journal-full-title] Cutis
  • [ISO-abbreviation] Cutis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 12
  •  go-up   go-down


12. Godambe SV, Rawal J: Blueberry muffin rash as a presentation of alveolar cell rhabdomyosarcoma in a neonate. Acta Paediatr; 2000 Jan;89(1):115-7
MedlinePlus Health Information. consumer health - Rashes.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Blueberry muffin rash as a presentation of alveolar cell rhabdomyosarcoma in a neonate.
  • Soft tissue sarcomas of childhood continue to present problems with pathologic diagnosis, staging and treatment.
  • Rhabdomyosarcoma, the most common soft tissue sarcoma, represents 4-8% of all malignant solid tumours in children.
  • We report a case of congenital alveolar rhabdomyosarcoma who presented with "blueberry muffin"-like rash.
  • A full-term female infant was noted at birth to have multiple skin lesions resembling blueberry muffin rash and an abdominal mass in the left iliac fossa, which appeared to be fixed to the posterior abdominal wall.
  • Biopsy from the mass confirmed the diagnosis of alveolar cell rhabdomyosarcoma.
  • The infant received chemotherapy but died within 1 mo of diagnosis.
  • [MeSH-major] Exanthema / etiology. Rhabdomyosarcoma, Alveolar / diagnosis. Soft Tissue Neoplasms / diagnosis
  • [MeSH-minor] Biopsy. Diagnosis, Differential. Female. Humans. Infant, Newborn. Skin / pathology

  • Genetic Alliance. consumer health - Rhabdomyosarcoma alveolar.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10677070.001).
  • [ISSN] 0803-5253
  • [Journal-full-title] Acta paediatrica (Oslo, Norway : 1992)
  • [ISO-abbreviation] Acta Paediatr.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] NORWAY
  •  go-up   go-down


13. Tari AS, Amoli FA, Rajabi MT, Esfahani MR, Rahimi A: Cutaneous embryonal rhabdomyosarcoma presenting as a nodule on cheek; a case report and review of literature. Orbit; 2006 Sep;25(3):235-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous embryonal rhabdomyosarcoma presenting as a nodule on cheek; a case report and review of literature.
  • We report a case of primary cutaneous rhabdomyosarcoma, solid embryonal type, presenting as a rapidly enlarging nodule on the right cheek of a 7-year-old boy.
  • It recurred 2 months later; at that time, incisional biopsy was consistent with malignant round cell tumor.
  • Subsequent immunohistochemical staining with desmin and myoglobin confirmed embryonal rhabdomyosarcoma.
  • The patient underwent radiation therapy followed by chemotherapy and continues to be disease free at 14 months after his wide local excision.
  • Rhabdomyosarcoma presenting as a dermal nodule is rare.
  • It usually presents as an asymptomatic papule without distinctive clinical features and therefore may result in delayed diagnosis unless a biopsy is performed.
  • [MeSH-major] Cheek. Facial Neoplasms / pathology. Rhabdomyosarcoma, Embryonal / pathology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Rhabdomyosarcoma embryonal.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16987772.001).
  • [ISSN] 0167-6830
  • [Journal-full-title] Orbit (Amsterdam, Netherlands)
  • [ISO-abbreviation] Orbit
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Desmin; 0 / Myoglobin
  • [Number-of-references] 18
  •  go-up   go-down


14. Kuroiwa M, Sakamoto J, Shimada A, Suzuki N, Hirato J, Park MJ, Sotomatsu M, Hayashi Y: Manifestation of alveolar rhabdomyosarcoma as primary cutaneous lesions in a neonate with Beckwith-Wiedemann syndrome. J Pediatr Surg; 2009 Mar;44(3):e31-5
SciCrunch. Clinical Genomic Database: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Manifestation of alveolar rhabdomyosarcoma as primary cutaneous lesions in a neonate with Beckwith-Wiedemann syndrome.
  • We report a rare case of neonatal Beckwith-Wiedemann syndrome (BWS) associated with alveolar rhabdomyosarcoma (RMS).
  • Chemotherapy was initiated and followed by bone marrow transplantation.
  • The patient, who is now 3 years and 11 months of age, is alive 46 months after the initial diagnosis, albeit with disease.
  • [MeSH-major] Beckwith-Wiedemann Syndrome / complications. Rhabdomyosarcoma, Alveolar / complications. Rhabdomyosarcoma, Alveolar / diagnosis. Skin Neoplasms / complications
  • [MeSH-minor] Antineoplastic Agents, Phytogenic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Transplantation. Camptothecin / analogs & derivatives. Camptothecin / therapeutic use. Cyclophosphamide / therapeutic use. Dactinomycin / therapeutic use. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Infant, Newborn. Potassium Channels, Voltage-Gated / genetics. Transcription, Genetic. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Rhabdomyosarcoma alveolar.
  • Genetic Alliance. consumer health - Beckwith-Wiedemann Syndrome.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19302842.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / KCNQ1OT1 protein, human; 0 / Potassium Channels, Voltage-Gated; 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 7673326042 / irinotecan; 8N3DW7272P / Cyclophosphamide; XT3Z54Z28A / Camptothecin; VAC protocol
  •  go-up   go-down


15. Miracco C, Materno M, De Santi MM, Pirtoli L, Ninfo V: Unusual second malignancies following radiation therapy: subcutaneous pleomorphic rhabdomyosarcoma and cutaneous melanoma. Two case reports. J Cutan Pathol; 2000 Sep;27(8):419-22
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual second malignancies following radiation therapy: subcutaneous pleomorphic rhabdomyosarcoma and cutaneous melanoma. Two case reports.
  • RESULTS: The first case showed histological, immunohistochemical and ultrastructural features of a rhabdomyosarcoma.
  • CONCLUSIONS: Rare cases of rhabdomyosarcomas and melanomas are induced by irradiation, although in some cases other factors (i.e., genetic risk, chemotherapy) may have a prominent etiopathogenetic role in their development.
  • A close follow-up and a careful examination of the irradiated area should facilitate an early diagnosis of these aggressive postradiation second neoplasms.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Endometrial Neoplasms / radiotherapy. Fibrosarcoma / radiotherapy. Melanoma / etiology. Neoplasms, Radiation-Induced / etiology. Rhabdomyosarcoma / etiology. Skin Neoplasms / etiology. Skin Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10955690.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] DENMARK
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


16. Donaldson SS, Meza J, Breneman JC, Crist WM, Laurie F, Qualman SJ, Wharam M, Children's Oncology Group Soft Tissue Sarcoma Committee (formely Intergroup Rhabdomyosarcoma Group) representing the Children's Oncology Group and the Quality Assurance Review Center: Results from the IRS-IV randomized trial of hyperfractionated radiotherapy in children with rhabdomyosarcoma--a report from the IRSG. Int J Radiat Oncol Biol Phys; 2001 Nov 1;51(3):718-28
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results from the IRS-IV randomized trial of hyperfractionated radiotherapy in children with rhabdomyosarcoma--a report from the IRSG.
  • PURPOSE: To evaluate the outcome and toxicity of hyperfractionated radiotherapy (HFRT) vs. conventionally fractionated radiotherapy (CFRT) in children with Group III rhabdomyosarcoma (RMS).
  • METHODS AND MATERIALS: Five hundred fifty-nine children were enrolled into the Intergroup Rhabdomyosarcoma Study IV with Group III RMS.
  • Of the 490 remaining, 239 were randomized to HFRT (59.4 Gy in 54 1.1-Gy twice daily fractions) and 251 to CFRT (50.4 Gy in 28 1.8-Gy daily fractions).
  • All patients received chemotherapy.
  • RT began at Week 9 after induction chemotherapy for all but those with high-risk parameningeal tumors who received RT during induction chemotherapy.
  • RESULTS: Analysis by randomized treatment assignment (intent to treat) revealed an estimated 5-year failure-free survival (FFS) rate of 70% and overall survival (OS) of 75%.
  • In the univariate analysis, the factors associated with the best outcome were age 1-9 years at diagnosis; noninvasive tumors; tumor size <5 cm; uninvolved lymph nodes; Stage 1 or 2 disease; primary site in the orbit or head and neck; and embryonal histologic features (p = 0.001 for all factors).
  • No differences in the FFS or OS between the two RT treatment methods and no differences in the FFS or OS between HFRT and CFRT were found when analyzed by age, gender, tumor size, tumor invasiveness, nodal status, histologic features, stage, or primary site.
  • Treatment compliance differed by age.
  • Of the children >or=5 years, 88% assigned to both HFRT and CFRT received their assigned treatment.
  • The reasons for not receiving the appropriate randomized treatment were progressive disease, early death, parent or physician refusal, young age, or surgery.
  • The toxicity assessment revealed more mucositis with HFRT (66%) than with CFRT (46%) (p = 0.03) for the parameningeal patients, and more skin reactions (16%) and nausea/vomiting (13%) with HFRT than with CFRT (7% and 5%, respectively) for patients with nonparameningeal primary tumors (p = 0.03 and p = 0.02, respectively).
  • The analysis by treatment actually received revealed a 5-year FFS rate of 73% and OS rate of 77%, with no difference between CFRT and HFRT.
  • The standard of care for Group III RMS continues to be CFRT with chemotherapy.
  • [MeSH-major] Dose Fractionation. Rhabdomyosarcoma / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Analysis of Variance. Child. Child, Preschool. Female. Humans. Infant. Male. Patient Compliance. Radiation Injuries / classification. Radiation Injuries / pathology. Remission Induction. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1579-80; author reply 1580 [12459396.001]
  • (PMID = 11597814.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-24507
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


17. Petitt M, Doeden K, Harris A, Bocklage T: Cutaneous extrarenal rhabdoid tumor with myogenic differentiation. J Cutan Pathol; 2005 Nov;32(10):690-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report the findings from a rare and very aggressive primary extrarenal rhabdoid tumor of the skin with myogenic differentiation.
  • Histological examination of the skin nodule as well as cytologic examination of a lymph node disclosed the characteristic rhabdoid phenotype.
  • The patient was aggressively treated with chemotherapy but ultimately died of her disease 8 months after presentation.
  • [MeSH-major] Rhabdoid Tumor / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Actins / analysis. Cell Differentiation. Desmin / analysis. Female. Humans. Immunohistochemistry. Intermediate Filaments / ultrastructure. Lymphatic Metastasis. Middle Aged. Muscle Development. Phenotype. Rhabdomyosarcoma / pathology. Vimentin / analysis

  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16293182.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Actins; 0 / Desmin; 0 / Vimentin
  •  go-up   go-down


18. Fernández-Teijeiro Alvarez A, Galán del Río P, Quintero Calcaño V, Montiano Jorge JI, Astigarraga Aguirre I, Navajas Gutiérrez A: [Subcutaneous nodules as a sign of malignant lymphoproliferative syndrome]. An Pediatr (Barc); 2009 Aug;71(2):148-52
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Skin involvement in children with malignant processes usually appears at the same time or after the diagnosis of the primary tumour.
  • We present the case of a girl with cutaneous involvement prior to the diagnosis of a malignant lymphoproliferative process.
  • After completing corticoid therapy for her respiratory process and transfusional support, the foot lesion had disappeared at discharge.
  • The skin biopsy confirmed malignant infiltration; the myelogram showed 6% blast infiltration, and both abdominal ultrasound and CT scan demonstrated lymph node involvement.
  • Immunophenotype confirmed the diagnosis of Precursor B Cell Lymphoblastic Leukemia-Lymphoma.
  • Although complete remission was achieved at the end of the induction chemotherapy according Euro-LB-02 protocol for stage IV, the patient presented a refractory leukaemia relapse thirteen months after diagnosis.
  • COMMENTARY: Malignancy should be suspected in the presence of a skin lesion with torpid evolution and biopsy should be considered.
  • Differential diagnosis of malignant skin lesions in children, especially in infants, must include mainly secondary involvement of leukaemia, lymphoma, metastases of neuroblastoma or rhabdomyosarcoma and less frequently other primary processes.
  • In our patient with an isolated cutaneous presentation, the progression of her malignant lymphoproliferative process could be modified by the corticotherapy given before the definitive diagnosis.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Female. Humans. Infant. Lymphoproliferative Disorders / diagnosis. Subcutaneous Tissue

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19477699.001).
  • [ISSN] 1695-4033
  • [Journal-full-title] Anales de pediatría (Barcelona, Spain : 2003)
  • [ISO-abbreviation] An Pediatr (Barc)
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


19. de Bruijn HS, Sluiter W, van der Ploeg-van den Heuvel A, Sterenborg HJ, Robinson DJ: Evidence for a bystander role of neutrophils in the response to systemic 5-aminolevulinic acid-based photodynamic therapy. Photodermatol Photoimmunol Photomed; 2006 Oct;22(5):238-46
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evidence for a bystander role of neutrophils in the response to systemic 5-aminolevulinic acid-based photodynamic therapy.
  • BACKGROUND/PURPOSE: A significant increase in the number of circulating and tumour neutrophils immediately after therapy was observed while investigating the increase in response of tissues to aminolevulinic acid-based photodynamic therapy (ALA-PDT) using a twofold illumination scheme with a prolonged dark interval.
  • The action of (tumour) neutrophils is an important therapeutic adjunct to the deposition of singlet oxygen within the treatment volume, for many photosensitizers.
  • METHODS: Rhabdomyosarcoma, transplanted in the thigh of female WAG/Rij rats were illuminated transdermally using 633 nm light following i.v. administration of 200 mg/kg ALA.
  • The pharmacokinetics of protoporphyrin IX (PpIX) within the tumour tissue during therapy were determined to compare with that observed in other models for topical administration of ALA.
  • The number of neutrophils in tumour and in the circulation were determined as a function of time after treatment and compared with growth delay of each scheme.
  • The number of neutrophils within the illuminated tumour and in the circulation increased significantly following therapy.
  • This increase in the number of neutrophils was associated with an increase in the efficacy of therapy: the more effective the therapy the greater the increase in tumour and blood neutrophils.
  • Administration of anti-granulocyte serum treatment prevented the influx of neutrophils after ALA-PDT, but did not lead to a significant decrease in the efficacy of the PDT treatment on the growth of the tumour for any illumination scheme investigated.
  • These data contribute to the understanding of the mechanism of response of tissue to systemic ALA-PDT.
  • [MeSH-major] Aminolevulinic Acid / pharmacology. Neutrophils / drug effects. Photochemotherapy. Photosensitizing Agents / pharmacology. Rhabdomyosarcoma / drug therapy. Skin Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16948825.001).
  • [ISSN] 0905-4383
  • [Journal-full-title] Photodermatology, photoimmunology & photomedicine
  • [ISO-abbreviation] Photodermatol Photoimmunol Photomed
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


20. Nag S, Tippin D, Ruymann FB: Long-term morbidity in children treated with fractionated high-dose-rate brachytherapy for soft tissue sarcomas. J Pediatr Hematol Oncol; 2003 Jun;25(6):448-52
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term morbidity in children treated with fractionated high-dose-rate brachytherapy for soft tissue sarcomas.
  • BACKGROUND: The purpose of this study was to determine the long-term local control, disease-free survival, and morbidity of fractionated high-dose-rate brachytherapy (F-HDR) in infants and children with soft tissue sarcomas.
  • PATIENTS AND METHODS: Fifteen children (13 girls and 2 boys, ages 5-101 months) with soft tissue sarcomas were treated with chemotherapy, organ-preserving surgery, and F-HDR (36 Gy in 12 fractions) to post-chemotherapy volumes.
  • External beam radiotherapy was not part of the primary treatment, although four patients (27%) subsequently received salvage external beam radiotherapy after treatment failure.
  • Chemotherapy was administered to all patients based on their tumor histology and stage.
  • There were two late complications associated with puberty that occurred 8 to 10 years after the initial treatments.
  • Acute toxicity occurred in five patients (38%) and consisted primarily of grade 1 to 3 skin and mucosal reactions.
  • CONCLUSIONS: As the sole radiation modality, F-HDR achieved excellent local control and disease-free survival in properly selected children with soft tissue sarcomas while preserving normal bone and organ development.
  • A significant percentage of patients experience adverse late sequelae as a result of this treatment.
  • [MeSH-major] Brachytherapy. Sarcoma / radiotherapy. Soft Tissue Neoplasms / radiotherapy
  • [MeSH-minor] Child. Child, Preschool. Combined Modality Therapy. Disease-Free Survival. Dose Fractionation. Dose-Response Relationship, Radiation. Female. Humans. Infant. Male. Morbidity. Neoplasm Recurrence, Local. Organ Preservation. Rhabdomyosarcoma / drug therapy. Rhabdomyosarcoma / mortality. Rhabdomyosarcoma / radiotherapy. Treatment Failure

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12794522.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Chami R, Aleynikova O, Abela A, Blais M, Oligny L, Bouron-Dal Soglio D, Patey N: [Juvenile xanthogranuloma of the nasal cavity]. Ann Pathol; 2010 Oct;30(5):374-7
MedlinePlus Health Information. consumer health - Nose Injuries and Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is the most frequent type of non-langerhans histiocytosis with a median age of 2 years.
  • The skin lesions tend to regress slowly with time.
  • When the lesions are numerous, they may persist, hence the need for treatment with corticosteroids or chemotherapy.
  • We report an 8-year old girl with JXG of early type without multinucleated and foamy cells.
  • This case presented as a tumour in the inferior meatus of nasal cavity, clinically simulating a rhabdomyosarcoma.
  • This atypical clinical and histological presentation with benign evolution should be recognized since it requires only local treatment.


22. Jurcić V, Perković T, Pohar-Marinsek Z, Hvala A, Lazar I: Infantile myofibroma in a prematurely born twin: a case report. Pediatr Dermatol; 2003 Jul-Aug;20(4):345-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Even solitary tumors need follow-up, as the type of presentation will be determined over time.
  • It is necessary to differentiate this entity from other more aggressive tumors, especially rhabdomyosarcoma, which is treated by chemotherapy prior to excision.
  • A fine-needle aspiration biopsy (FNAB) specimen obtained soon after her birth suggested a diagnosis of benign neoplasm.
  • The tumor was excised 1 month later, at which time it was significantly enlarged, ulcerated, and also exhibited worrisome histologic features including mitoses and infiltrative growth.
  • [MeSH-major] Diseases in Twins. Infant, Premature, Diseases / pathology. Leiomyoma / congenital. Leiomyoma / pathology. Skin Neoplasms / congenital. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Premature Babies.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12869160.001).
  • [ISSN] 0736-8046
  • [Journal-full-title] Pediatric dermatology
  • [ISO-abbreviation] Pediatr Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Ejaz A, Wenig BM: Sinonasal undifferentiated carcinoma: clinical and pathologic features and a discussion on classification, cellular differentiation, and differential diagnosis. Adv Anat Pathol; 2005 May;12(3):134-43
Genetic Alliance. consumer health - Sinonasal undifferentiated carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sinonasal undifferentiated carcinoma: clinical and pathologic features and a discussion on classification, cellular differentiation, and differential diagnosis.
  • Adjunct analyses (eg, immunohistochemistry, electron microscopy, and molecular biologic studies) are often required in the diagnosis of SNUC and in differentiating it from other undifferentiated malignant neoplasms.
  • The treatment of SNUC includes aggressive multimodality therapy, including surgical resection and adjuvant therapy (ie, radiotherapy, chemotherapy).
  • The prognosis associated with SNUC is poor, and death due to disease often occurs within short periods following the diagnosis.
  • Irrespective of its cell of origin and perhaps even in the face of differentiated foci in limited parts of the tumor, given its rather unique clinicopathologic characteristics, this tumor should be identified and classified as SNUC, thereby differentiating it from the other specific types of sinonasal carcinomas and nonepithelial malignant tumors.
  • [MeSH-minor] Adult. Aged. Carcinoma, Neuroendocrine / pathology. Diagnosis, Differential. Esthesioneuroblastoma, Olfactory / pathology. Humans. Lymphoma, T-Cell, Cutaneous / pathology. Male. Melanoma / pathology. Middle Aged. Nasal Cavity / pathology. Nose Neoplasms / pathology. Prognosis. Rhabdomyosarcoma / pathology. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15900114.001).
  • [ISSN] 1072-4109
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 29
  •  go-up   go-down


24. Brekken RA, Overholser JP, Stastny VA, Waltenberger J, Minna JD, Thorpe PE: Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res; 2000 Sep 15;60(18):5117-24
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At the present time there are two well-characterized receptors for VEGF that are selectively expressed on endothelium.
  • 2C3 blocks the VEGF-induced vascular permeability increase in guinea pig skin.
  • [MeSH-minor] Animals. Capillary Permeability / drug effects. Carcinoma, Non-Small-Cell Lung / pathology. Carcinoma, Non-Small-Cell Lung / therapy. Cell Division / drug effects. Enzyme-Linked Immunosorbent Assay. Fibrosarcoma / pathology. Fibrosarcoma / therapy. Guinea Pigs. Humans. Lung Neoplasms / pathology. Lung Neoplasms / therapy. Male. Mice. Neoplasm Transplantation. Phosphorylation / drug effects. Proto-Oncogene Proteins / metabolism. Receptors, Vascular Endothelial Growth Factor. Rhabdomyosarcoma / pathology. Rhabdomyosarcoma / therapy. Skin / blood supply. Substrate Specificity. Transplantation, Heterologous. Vascular Endothelial Growth Factor A. Vascular Endothelial Growth Factor Receptor-1. Vascular Endothelial Growth Factors

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11016638.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1RO1 CA74951; United States / NCI NIH HHS / CA / 5RO CA54168; United States / NIGMS NIH HHS / GM / T32 GM07062; etc
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Endothelial Growth Factors; 0 / Growth Inhibitors; 0 / Lymphokines; 0 / Proto-Oncogene Proteins; 0 / Receptors, Growth Factor; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factors; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-1
  •  go-up   go-down


25. Rodriguez-Galindo C, Crews KR, Stewart CF, Furman W, Panetta JC, Daw NC, Cain A, Tan M, Houghton PH, Santana VM: Phase I study of the combination of topotecan and irinotecan in children with refractory solid tumors. Cancer Chemother Pharmacol; 2006 Jan;57(1):15-24
Hazardous Substances Data Bank. Topotecan .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DLTs were neutropenia (n = 8), typhlitis (n = 5), and skin rash (n = 1).
  • One patient with neuroblastoma and one with rhabdomyosarcoma had a partial and a complete response, respectively.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Camptothecin / adverse effects. Camptothecin / analogs & derivatives. Camptothecin / pharmacokinetics. Camptothecin / therapeutic use. Child. Child, Preschool. Drug Administration Schedule. Humans. Topotecan / adverse effects. Topotecan / pharmacokinetics. Topotecan / therapeutic use. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16001174.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 23099; United States / NCI NIH HHS / CA / P30 CA 21765
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 7673326042 / irinotecan; 7M7YKX2N15 / Topotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


26. Zywietz F, Böhm L, Sagowski C, Kehrl W: Pentoxifylline enhances tumor oxygenation and radiosensitivity in rat rhabdomyosarcomas during continuous hyperfractionated irradiation. Strahlenther Onkol; 2004 May;180(5):306-14
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumors were irradiated with (60)Co gamma-irradiation using single doses (15 and 30 Gy), conventional fractionation (60 Gy/30 fractions/6 weeks), and continuous hyperfractionation (54 Gy/36 fractions/18 days) in combination with PTX or an equivalent volume of physiological saline.
  • RESULTS: PTX increased tumor oxygenation for up to 45 min after administration of the drug.
  • Single doses of 15 and 30 Gy of irradiation, when combined with PTX, produced little radiosensitization of the R1H tumors as indicated by dose-modifying factors (DMFs) of 1.11 and 1.04, respectively.
  • Given to rats as an adjuvant to fractionated irradiation, PTX does not enhance acute or late skin reactions or tumor metastasis.
  • [MeSH-major] Oxygen / metabolism. Pentoxifylline / administration & dosage. Radiation Tolerance / drug effects. Rhabdomyosarcoma / metabolism. Rhabdomyosarcoma / therapy
  • [MeSH-minor] Animals. Cell Survival / drug effects. Cell Survival / radiation effects. Combined Modality Therapy / methods. Dose Fractionation. Dose-Response Relationship, Radiation. Male. Platelet Aggregation Inhibitors / administration & dosage. Radiotherapy Dosage. Rats. Treatment Outcome

  • Hazardous Substances Data Bank. OXYGEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15127161.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Platelet Aggregation Inhibitors; S88TT14065 / Oxygen; SD6QCT3TSU / Pentoxifylline
  •  go-up   go-down


27. Zhou H, Shen T, Luo Y, Liu L, Chen W, Xu B, Han X, Pang J, Rivera CA, Huang S: The antitumor activity of the fungicide ciclopirox. Int J Cancer; 2010 Nov 15;127(10):2467-77
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ciclopirox olamine (CPX) is a synthetic antifungal agent clinically used to treat mycoses of the skin and nails.
  • The results indicate that CPX inhibited cell proliferation and induced apoptosis in human rhabdomyosarcoma (Rh30), breast carcinoma (MDA-MB231) and colon adenocarcinoma (HT-29) cells in a concentration-dependent manner.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosci Res. 1999 Nov 1;58(3):396-406 [10518113.001]
  • [Cites] Blood. 2009 Oct 1;114(14):3064-73 [19589922.001]
  • [Cites] J Am Acad Dermatol. 2000 Oct;43(4 Suppl):S57-69 [11051135.001]
  • [Cites] Int J Dermatol. 2001 May;40(5):305-10 [11554991.001]
  • [Cites] Mol Cells. 2003 Feb 28;15(1):55-61 [12661761.001]
  • [Cites] Curr Med Chem. 2003 Jun;10(12):1021-34 [12678674.001]
  • [Cites] Antimicrob Agents Chemother. 2003 Jun;47(6):1805-17 [12760852.001]
  • [Cites] Mol Cancer Ther. 2003 Jun;2(6):573-80 [12813137.001]
  • [Cites] Cell Prolif. 2003 Jun;36(3):131-49 [12814430.001]
  • [Cites] Blood. 2004 Sep 1;104(5):1450-8 [15150082.001]
  • [Cites] Arzneimittelforschung. 1973 May;23(5):670-4 [4197001.001]
  • [Cites] Arzneimittelforschung. 1981;31(8A):1328-32 [7197539.001]
  • [Cites] Drugs. 1985 Apr;29(4):330-41 [3158508.001]
  • [Cites] Blood. 1990 May 15;75(10):1903-19 [2186818.001]
  • [Cites] Cytometry. 1991;12(1):26-32 [1900227.001]
  • [Cites] Clin Dermatol. 1991 Oct-Dec;9(4):471-7 [1822407.001]
  • [Cites] Nature. 1993 Dec 16;366(6456):701-4 [8259214.001]
  • [Cites] J Neurosci. 1996 Feb 1;16(3):1150-62 [8558244.001]
  • [Cites] Science. 1997 Dec 12;278(5345):1966-8 [9395403.001]
  • [Cites] EMBO J. 1998 Aug 10;17(5):1268-78 [9482724.001]
  • [Cites] J Biol Chem. 1998 Apr 24;273(17):10618-23 [9553123.001]
  • [Cites] Genes Dev. 1999 Jun 15;13(12):1501-12 [10385618.001]
  • [Cites] Int J Cancer. 2006 Aug 15;119(4):757-64 [16550606.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Oct 3;103(40):14901-6 [17003122.001]
  • [Cites] FEMS Yeast Res. 2007 May;7(3):404-12 [17233764.001]
  • [Cites] Nat Rev Mol Cell Biol. 2008 Jan;9(1):47-59 [18097445.001]
  • [Cites] J Clin Oncol. 2008 Mar 1;26(7):1106-11 [18309945.001]
  • [Cites] Cell Cycle. 2008 Apr 1;7(7):842-7 [18414039.001]
  • [Cites] Oncogene. 2008 Oct 27;27(50):6452-61 [18955972.001]
  • [Cites] Trends Cell Biol. 2008 Nov;18(11):528-35 [18805009.001]
  • [Cites] Nat Rev Cancer. 2008 Sep;8(9):671-82 [18650841.001]
  • [Cites] Cancer Res. 2009 Feb 1;69(3):948-57 [19176392.001]
  • [Cites] Nat Rev Cancer. 2009 Mar;9(3):153-66 [19238148.001]
  • [Cites] J Cell Biol. 2009 Apr 20;185(2):193-202 [19364923.001]
  • [Cites] Nat Rev Drug Discov. 2009 Jul;8(7):579-91 [19478820.001]
  • [Cites] Front Biosci. 2006;11:1164-88 [16146805.001]
  • (PMID = 20225320.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA115414-04; United States / NCI NIH HHS / CA / R37 CA046120-19; United States / NCI NIH HHS / CA / R01 CA115414; United States / NCI NIH HHS / CA / R37 CA046120; United States / NCI NIH HHS / CA / CA115414
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCL2L1 protein, human; 0 / BIRC5 protein, human; 0 / CDKN1A protein, human; 0 / Caspase Inhibitors; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Cyclins; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Pyridones; 0 / Retinoblastoma Protein; 0 / bcl-X Protein; 19W019ZDRJ / ciclopirox; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases; EC 2.7.11.22 / CDK2 protein, human; EC 2.7.11.22 / CDK4 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinase 2; EC 2.7.11.22 / Cyclin-Dependent Kinase 4; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspase 7
  • [Other-IDs] NLM/ NIHMS180784; NLM/ PMC2888914
  •  go-up   go-down


28. Rahbeeni F, Hendrikse AS, Smuts CM, Gelderblom WC, Abel S, Blekkenhorst GH: The effect of evening primrose oil on the radiation response and blood flow of mouse normal and tumour tissue. Int J Radiat Biol; 2000 Jun;76(6):871-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of evening primrose oil on the radiation response and blood flow of mouse normal and tumour tissue.
  • PURPOSE: To investigate the effect of the oral administration of evening primrose oil on the radiation response and the blood flow of normal tissue and a tumour in BALB/c mice.
  • METHODS AND MATERIALS: Aliquots of evening primrose oil were fed to BALB/c mice daily and the radiation response of the skin was assessed by the determination of ED50 values for the incidence of moist desquamation, using probit analysis.
  • Tumour radiosensitivity was investigated by determining the growth delay caused by irradiation of a transplantable rhabdomyosarcoma.
  • The 86RbCl uptake technique was used to determine the blood flow in normal foot and tumour tissue.
  • The fatty-acid content of red blood cells, plasma and tumour tissue was measured using gas chromatography.
  • RESULTS: Daily evening primrose oil dietary supplementation reduced the sensitivity of skin to radiation-induced moist desquamation and prevented the radiation-associated increase in blood flow that was observed in this tissue.
  • There were no changes in tumour fatty-acid levels as a result of evening primrose oil treatment.
  • CONCLUSIONS: Daily evening primrose oil supplementation reduced the sensitivity of skin to radiation-induced moist desquamation but did not alter tumour sensitivity to radiation.
  • [MeSH-major] Fatty Acids, Essential / pharmacology. Radiation Tolerance / drug effects. Sarcoma, Experimental / drug therapy. Sarcoma, Experimental / radiotherapy
  • [MeSH-minor] Administration, Oral. Animals. Blood Flow Velocity / drug effects. Blood Flow Velocity / radiation effects. Erythrocytes / drug effects. Erythrocytes / metabolism. Fatty Acids / blood. Fatty Acids / metabolism. Female. Linoleic Acids. Mice. Mice, Inbred BALB C. Plant Oils. Radiation-Sensitizing Agents / administration & dosage. Radiation-Sensitizing Agents / pharmacology. Vasodilation / drug effects. Vasodilation / radiation effects. gamma-Linolenic Acid

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10902742.001).
  • [ISSN] 0955-3002
  • [Journal-full-title] International journal of radiation biology
  • [ISO-abbreviation] Int. J. Radiat. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Fatty Acids; 0 / Fatty Acids, Essential; 0 / Linoleic Acids; 0 / Plant Oils; 0 / Radiation-Sensitizing Agents; 65546-85-2 / Efamol; 78YC2MAX4O / gamma-Linolenic Acid
  •  go-up   go-down






Advertisement